Flash Finance

Indraprastha Medical Corporation LimitedINDRAMEDCOCorporate

Healthcare Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹320.05
MCap ₹2,934 Cr · P/E 15.6
Indraprastha Medical Corporation Limited — Stock analysis & AI research Indraprastha Medical Corporation Limited — Seasonality — best & worst months Indraprastha Medical Corporation Limited — Technical indicators & charts Indraprastha Medical Corporation Limited — Technical setup — score, trend, support & resistance Indraprastha Medical Corporation Limited — Descending Channel pattern forming Indraprastha Medical Corporation Limited — Live exchange announcements
📋 High ROE Stocks📋 High ROCE Stocks📋 High Interest Coverage Stocks📋 Stocks Cheaper Than Their Industry📋 High Profit Growth Stocks📋 GARP Stocks (PEG Below 1) 📈 New 52-Week Low Stocks📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹406 Cr
Sales · Jun 2026
+11.3% YoY
₹80 Cr
Operating Profit · Jun 2026
+9.3% YoY
19.7%
OPM % · Jun 2026
-1.5% YoY
₹56 Cr
Net Profit · Jun 2026
+9.5% YoY
₹6.09
EPS · Jun 2026
+8.6% YoY

📝 Indraprastha Medical Corporation Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Indraprastha Medical Corporation Limited reported revenue of ₹406 crore for the quarter ended June 2026 (Q1 FY27), up 11.3% from ₹365 crore in the same quarter last year, and up 11.3% sequentially over the March 2026 quarter.

Net profit rose 9.5% year-on-year to ₹56 crore, from ₹51 crore. Earnings per share (EPS) came in at ₹6.09.

Operating profit stood at ₹80 crore — an operating margin (OPM) of 19.7%, compared with 20.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Indraprastha Medical Corporation Limited posted revenue of ₹1,483 crore, a growth of 9.3% over FY25, with a net profit of ₹183 crore (up 13.7% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,524 crore with a net profit of ₹188 crore.

Valuation snapshot

At the current price of ₹320.05, INDRAMEDCO has a market capitalisation of ₹2,934 crore and a trailing P/E of about 15.6.

Within the Healthcare industry, it is the 8th-largest of the 22 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.00%, foreign institutional investors (FIIs) 2.39%, domestic institutional investors (DIIs) 1.77%, public shareholders 44.84% of Indraprastha Medical Corporation Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹2,934 Cr
Current Price ?
₹320.1
P/E ?
15.58below ind
Industry P/E ?
34.70
P/B ?
3.96
P/S ?
1.92
P/FCF ?
27.17
Enterprise Value ?
₹2,971 Cr
EV/EBITDA ?
10.84
PEG ?
0.56
Earnings Yield ?
7.7%
Dividend Yield ?
1.39%
Profitability & Returns
Sales (TTM) ?
₹1,524 Cr
OPM ?
18.0%
Profit after tax (TTM) ?
₹188 Cr
EPS (TTM) ?
₹20.54
ROCE ?
36.0%
ROE ?
25.4%
ROA ?
19.0%
Growth
Sales — latest qtr ?
₹406 Cr
PAT — latest qtr ?
₹56 Cr
YoY qtr sales growth ?
11.3%
YoY qtr profit growth ?
9.5%
Sales growth (3y) ?
11%
Sales growth (5y) ?
19%
Profit growth (3y) ?
28%
Profit growth (5y) ?
132%
Financial Health
Debt ?
₹37 Cr
Debt to Equity ?
0.05
Interest Coverage ?
40.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.00%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-13.7%
Return 6 months ?
-25.1%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 274307317306315348350325334365381372365406 +11.3% +11.3%
Operating Profit 3347504748676452617371626180 +9.3% +30.8%
Other Income 54445565677778 +20.3% +20.3%
Interest 11112222122112 -17.5% +65.0%
Depreciation 1010101010111111111011111112 +17.6% +6.9%
Profit Before Tax 2740444142605745556866565575 +10.0% +36.0%
Net Profit 2030332931454233415149414256 +9.5% +33.0%
EPS 2.163.333.583.213.404.884.633.584.475.615.404.474.556.09 +8.6% +33.8%
OPM % 12.0% 15.3% 15.8% 15.4% 15.2% 19.3% 18.2% 16.0% 18.3% 20.0% 18.7% 16.7% 16.7% 19.7% -1.5% +18.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹1,357 Cr ₹1,483 Cr ₹1,524 Cr +9.3%
Operating Profit ₹244 Cr ₹267 Cr ₹274 Cr +9.7%
OPM % 17.96% 18.02% 17.98% +0.3%
NPM % 11.90% 12.37% 12.35% +3.9%
Other Income ₹22 Cr ₹28 Cr ₹30 Cr +28.7%
Depreciation ₹44 Cr ₹43 Cr ₹45 Cr -3.0%
Interest ₹7 Cr ₹6 Cr ₹5 Cr -16.4%
EBIT ₹199 Cr ₹224 Cr ₹230 Cr +12.5%
PBT ₹217 Cr ₹245 Cr ₹252 Cr +13.1%
Tax ₹15 Cr ₹17 Cr ₹36 Cr +16.0%
Net Profit ₹161 Cr ₹183 Cr ₹188 Cr +13.7%
EPS ₹17.56 ₹20.03 ₹20.51 +14.1%
Material Cost ₹56 Cr ₹65 Cr ₹136 Cr +16.4%
Employee Cost ₹72 Cr ₹74 Cr ₹147 Cr +2.8%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 92929292 +0.0%
Reserves 288386505649 +28.5%
Borrowings 2343337 +12.1%
Other Liabilities 173212222214 -3.6%
Total Liabilities 555723852991 +16.3%
Fixed Assets 275347328365 +11.3%
CWIP 30333 -90.9%
Investments -0-0-0-0 —
Other Assets 278376491624 +27.1%
Total Assets 555723852991 +16.3%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 144200157167 +6.4%
Cash from Investing Activity -108-158-111-178 -60.4%
Cash from Financing Activity -26-32-46-46 +0.0%
Net Cash Flow 119-0-57 —
Free Cash Flow 100131120108 -10.0%
CFO/OP 102%127%89%88% -1.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 23172028 +40.0%
Inventory Days ———11 —
Days Payable ———182 —
Cash Conversion Cycle 231720-144 -820.0%
Working Capital Days -12-24-19-4 +78.9%
ROCE % 34%38%39%36% -7.7%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 51.00%51.00%51.00%51.00%51.00% +0.0%
FIIs 2.73%2.41%2.72%2.43%2.39% -1.6%
DIIs 3.56%3.51%0.82%0.87%1.77% +103.4%
Public 42.74%43.08%45.43%45.69%44.84% -1.9%
No. of Shareholders 70,21170,91471,22572,98077,706 +6.5%

⚖️ Peer comparison

Industry: Healthcare · 22 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 VIJAYA Vijaya Diagnostic ₹1,507.80 15,530 82.7 857 187 42.3% 21.8% 19.5% 20.2% 22.8% 37.3%
2 METROPOLIS Metropolis Healthcare ₹596.30 12,370 61.1 1,710 203 24.7% 11.9% 23.6% 31.4% 16.6% 25.7%
3 HCG Healthcare Global ₹704.05 10,512 390.9 2,626 33 18.2% 1.3% 14.6% -53.3% 13.1% 175.3%
4 YATHARTH Yatharth Hospital ₹988.90 9,528 54.1 1,200 171 23.6% 14.3% 36.2% 31.6% 47.6% 16.2%
5 JLHL Jupiter Life ₹277.85 9,109 9.7 1,557 187 22.1% 12.0% 20.9% -6.7% 18.2% -14.5%
6 THYROCARE Thyrocare Technologies ₹555.45 8,841 50.0 876 176 32.1% 20.1% 20.8% 79.4% 24.3% 33.2%
7 KOVAI Kovai Medical ₹6,260.50 6,850 26.7 1,644 256 27.9% 15.6% 15.7% 16.7% 15.3% 20.6%
8 INDRAMEDCO Indraprastha Medical ₹363.20 3,330 17.7 1,524 188 18.0% 12.4% 9.3% 13.7% 11.3% 9.5%
9 KRSNAA Krsnaa Diagnostics ₹543.40 1,763 18.1 816 98 26.8% 12.0% 7.8% 31.0% 22.1% -19.3%
10 SURAKSHA Suraksha Diagnostic ₹311.85 1,624 45.3 325 35 31.4% 10.8% 23.1% 1.4% 20.7% 40.0%
11 SHALBY Shalby ₹132.15 1,418 38.0 1,176 37 12.1% 3.2% 5.0% 1683.0% 11.7% 36.7%
12 GPTHEALTH GPT Healthcare ₹157.90 1,296 27.4 491 48 18.5% 9.8% 15.1% -21.9% 17.8% 62.5%
13 LAXMIDENTL Laxmi Dental ₹196.21 1,080 35.0 287 31 16.2% 10.9% 16.0% -10.1% 13.2% 28.9%
14 NEPHROCARE Nephro Care ₹234.80 387 — — — — — — — 68.4% 347.7%
15 LOTUSEYE Lotus Eye ₹114.50 243 n/m 57 0 8.5% 0.3% 8.4% -89.1% 26.2% 13.0%
16 UNIHEALTH Unihealth Hospitals ₹121.00 190 6.5 132 46 40.9% 34.8% — — 104.6% 71.5%
17 MADHAVBAUG Vaidya Sane ₹148.00 156 19.1 147 8 11.4% 5.6% — — 116.1% 94.3%
18 MHHL Mohini Health ₹57.05 104 — 145 -17 -1.4% -11.7% — — -6.6% -1400.0%
19 MAITREYA Maitreya Medicare ₹120.65 82 — 45 -2 -1.0% -5.5% — — -5.2% -1720.0%
20 AATMAJ Aatmaj Healthcare ₹26.75 60 83.6 24 1 9.7% 2.9% — — 22.5% -39.4%
21 NIDAN Nidan Laborator. ₹33.00 46 30.6 26 2 19.0% 5.9% — — -11.2% -92.0%
22 ARTEMISMED Artemis Medicare ₹315.00 — 48.0 1,081 103 17.4% 9.6% 15.4% 25.9% 16.3% 30.9%
❓ Frequently asked questions
What was Indraprastha Medical Corporation Limited's revenue in Q1 FY27?
Indraprastha Medical Corporation Limited reported revenue of ₹406 crore for the quarter ended June 2026 (Q1 FY27), up 11.3% from ₹365 crore in the same quarter last year, and up 11.3% sequentially over the March 2026 quarter.
What was Indraprastha Medical Corporation Limited's net profit in Q1 FY27?
Net profit rose 9.5% year-on-year to ₹56 crore, from ₹51 crore. Earnings per share (EPS) came in at ₹6.09.
What is INDRAMEDCO's market capitalisation and P/E ratio?
At the current price of ₹320.05, INDRAMEDCO has a market capitalisation of ₹2,934 crore and a trailing P/E of about 15.6.
Who owns Indraprastha Medical Corporation Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.00%, foreign institutional investors (FIIs) 2.39%, domestic institutional investors (DIIs) 1.77%, public shareholders 44.84% of Indraprastha Medical Corporation Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI